Form 4: Enliven Therapeutics Chief Scientific Officer Sells Shares Under Pre-Arranged Trading Plan

Enliven Therapeutics' Chief Scientific Officer, Joseph P. Lyssikatos, sold 7,500 shares of common stock for approximately $20.03 per share as part of a pre-established Rule 10b5-1 trading plan.

Summary

• Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, Inc. (ELVN), reported the sale of 7,500 shares of common stock.
• The transaction occurred on June 3, 2025, at a weighted average price of $20.0293 per share, totaling approximately $150,219.75.
• Following this transaction, Mr. Lyssikatos beneficially owns 977,688 shares of Enliven Therapeutics common stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Lyssikatos on November 15, 2024.
• The shares beneficially owned after the transaction are held directly and indirectly, with the indirect shares held by The Lyssikatos Revocable Trust 12/15/2011, for which Mr. Lyssikatos serves as trustee.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can sometimes be viewed negatively, the fact that it was conducted under a pre-arranged Rule 10b5-1 plan mitigates concerns that it is based on negative undisclosed information. It is a routine liquidity event for an executive.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating it was not based on new, non-public information and is a planned liquidity event.

Negatives

• An insider sale, even under a 10b5-1 plan, reduces the direct ownership stake of a key executive, which some investors might interpret as a slight reduction in alignment with shareholder interests.

Future Outlook

NA

Management Comments

• "The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024."
• "This transaction was executed in multiple trades at prices ranging from $20.00 to $20.11. The price reported above reflects the weighted average sale price."
• "The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."
• "The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee."

Industry Context

This Form 4 filing details an individual insider transaction and does not provide broader industry context or trends. It is a routine disclosure of a pre-planned stock sale by a company executive.

Related Party Transactions

• The shares beneficially owned after the transaction are held indirectly by The Lyssikatos Revocable Trust 12/15/2011, for which the Reporting Person serves as trustee. This represents a transaction or holding structure involving a related party (the executive's trust).

Stakeholder Impact

• Shareholders: The sale by a Chief Scientific Officer, even under a 10b5-1 plan, slightly reduces insider ownership, which could be perceived as a minor decrease in alignment, though it's a common practice for executive compensation and liquidity.
• Employees, Customers, Suppliers, Creditors: No direct impact is indicated by this specific filing.

Key Dates

Keywords

Enliven Therapeutics, ELVN, Joseph P. Lyssikatos, Insider Sale, Form 4, SEC Filing, Chief Scientific Officer, Rule 10b5-1, Stock Transaction, Beneficial Ownership